Cost-Effectiveness Considerations to Restrict Access in the US?
This is a discussion on Cost-Effectiveness Considerations to Restrict Access in the US? within the Other Clinical Pharmacy News forum, part of the Industry News and Updates category; Coverage decisions for cancer drugs that take into account cost effectiveness are associated with slower time to coverage and more ...
|
|||||||
| Register | Help | Members List | Mark Forums Read |
07-16-2010, 05:05 PM
|
|||
|
|||
Cost-Effectiveness Considerations to Restrict Access in the US?
Coverage decisions for cancer drugs that take into account cost effectiveness are associated with slower time to coverage and more restrictions.
Medscape Medical News More... 
|
 |
«
Previous Thread
|
Next Thread
»
| Thread Tools | |
| Display Modes | |
Linear Mode
|
|
|
||||
| Thread | Thread Starter | Forum | Replies | Last Post |
| Health Insurers Frequently Misclassify Physicians as Low-Cost or High-Cost Providers, RAND Reports | industry_news | Other Clinical Pharmacy News | 0 | 03-18-2010 01:30 PM |
| Prasugrel "Economically Attractive" Treatment Based on Cost-Effectiveness Analysis | industry_news | Other Clinical Pharmacy News | 0 | 01-11-2010 02:02 PM |
| Access to Iplex for Patients with ALS | industry_news | FDA News | 0 | 07-27-2009 04:03 PM |
| FDA May Restrict Acetaminophen | industry_news | Other Clinical Pharmacy News | 0 | 07-01-2009 01:24 PM |
| DRAFT: Methods Reference Guide for Effectiveness and Comparative Effectiveness Reviews | industry_news | Comparative Effectiveness Updates | 0 | 04-10-2008 08:22 PM |
© 2008 DrugManagementForum™ powered by |
 |